SGSarah A. Gaussoin

Sarah A. Gaussoin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah A. Gaussoin has a total of 155 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plasma biomarker levels and cognitive decline in a heterogenous community-based cohort with multiple comorbidities

    by Marc D. Rudolph, Julia R. Bacci, Jillian K. Lee, Sarah A. Gaussoin, James R. Bateman, Timothy M. Hughes, Shannon L. Risacher, Laura D. Baker, Goldie S. Byrd, Courtney L. Sutphen, et al.

    INTRODUCTION: Knowledge about how Alzheimer’s disease (AD) and AD-related dementia (AD/ADRD) plasma biomarkers relate to global and domain-specific cognitive functioning across diagnostic groups remains limited, particularly in heterogeneous, community-dwelling populations with multiple comorbidities. METHODS: We evaluated associations between baseline plasma biomarker levels (Aβ42/40, p-tau181, p-tau217, NfL, GFAP) and cognitive performance at baseline and longitudinally (up to 7 years). Participants (n=590) enrolled in the Wake Forest Alzheimer’s Disease Research Center Clinical Core (314 cognitively unimpaired [CU]; 206 mild cognitive impairment [MCI]; and 70 dementia) completed annual cognitive assessments including the Uniform Data Set (UDSv3; NACC). Domain-specific cognitive composites including memory, executive function, attention, language, visuospatial ability, and phonemic fluency, as well as a modified Preclinical Alzheimer’s Cognitive Composite (PACC5), were evaluated. General linear and mixed-effects models were adjusted for demographics (age, sex, race, education), APOE-ε4 status, comorbidities (estimated glomerular filtration rate; BMI), and cardiometabolic health factors (hypertension, diabetes). Effect modification by cognitive diagnosis was evaluated. RESULTS: Baseline plasma biomarkers, particularly p-tau217, were associated with poorer baseline cognitive performance and greater longitudinal decline on the PACC5 and all cognitive domains assessed, except phonemic fluency (strongest for memory). Post-hoc analyses indicated associations between plasma biomarker levels and cognition were generally more pronounced in MCI compared with CU participants. Effect modification by baseline cognitive status was limited and attenuated when all biomarkers were modeled simultaneously. Comorbidities and cardiometabolic factors modified select associations. DISCUSSION: Plasma AD/ADRD biomarkers, particularly p-tau217, were associated with cognitive impairment and decline in a heterogenous community cohort. HIGHLIGHTS: The WF ADRC is a clinically heterogeneous, comorbidity-rich community-dwelling cohort Plasma AD/ADRD biomarkers were associated with poorer baseline cognition and longitudinal cognitive decline Associations were strongest for the PACC5 composite and memory-related cognitive domains p-tau217 provided the most robust biomarker signal across models

  • Obesity, cardiometabolic health status, and brain health in community-dwelling older adults

    by Kathryn H Alphin, Cynthia K Suerken, Marc D Rudolph, Sarah Gaussoin, Samuel N Lockhart, Suzanne Craft, Tina E Brinkley

    Background: Though mid-life obesity is a known risk factor for dementia, how obesity in late life impacts brain health is not well understood, especially in the presence of comorbid risk factors like hypertension (HTN) and impaired glucose tolerance (IGT). Objective: We investigated associations between obesity, neuroimaging measures, and cognition in middle aged and older adults, specifically testing whether higher body mass index (BMI), waist circumference (WC), and waist-to-hip ratio are associated with brain health independent of HTN and IGT. Methods: A total of 599 participants with brain MRI, cognitive testing, and anthropometric measurements were examined. Chi square and one-way ANOVA tests were performed to compare participant characteristics across BMI categories. Linear regression models assessed relationships between anthropometric, neuroimaging, and cognitive outcomes with and without adjustment for relevant covariates. We also explored interactions between anthropometric measures and APOE ε4 status and cognitive status. Results: Higher BMI was associated with higher cerebral blood flow (CBF) in both white matter (β = 0.2294 ± 0.0431, p < 0.001) and gray matter (β = 0.0872 ± 0.0405, p = 0.032), higher free water (β = 0.0906 ± 0.0425, p = 0.034), lower fractional anisotropy (β = -0.0891 ± 0.0433, p = 0.040), and better global cognition (β = 0.022 ± 0.007, p = 0.002) and cognitive composite scores (ps < 0.01), independent of IGT and HTN. Similar associations were observed for waist circumference. Evidence of effect modification by APOE ε4 carrier status and cognitive status were found for white matter CBF, white matter hyperintensities, fractional anisotropy, and cognition. Conclusions: Obesity measures are positively associated with better brain structure, function, and cognition in aging adults, highlighting the importance of managing body weight in older age to maintain optimal brain health.

  • Long-Term Effect of Intensive vs Standard Blood Pressure Control on Mild Cognitive Impairment and Probable Dementia in SPRINT

    by David M. Reboussin, Sarah A. Gaussoin, Nicholas M. Pajewski, Byron C. Jaeger, Bonnie Sachs, Stephen R. Rapp, Mark A. Supiano, Maryjo L. Cleveland, Valerie Hunter, Jamehl L. Demons, et al.


  • Long-Term Effect of Intensive vs Standard Blood Pressure Control on Mild Cognitive Impairment and Probable Dementia in SPRINT

    by David M. Reboussin, Sarah A. Gaussoin, Nicholas M. Pajewski, Byron C. Jaeger, Bonnie Sachs, Stephen R. Rapp, Mark A. Supiano, Maryjo L. Cleveland, Valerie Hunter, Jamehl L. Demons, et al.

    The Systolic Blood Pressure Intervention Trial suggested that intensive lowering of systolic blood pressure (SBP) decreases the risk of developing dementia. However, an insufficient number of probable dementia cases stemming from the trial's early termination made results inconclusive. The goal of this study was to estimate the effect of intensive vs standard SBP lowering on the longer term incidence of cognitive impairment leveraging extended follow-up for cognitive status. This is a prespecified secondary analysis of a randomized clinical trial. Between 2010 and 2013, patients aged 50 years and older with hypertension and increased cardiovascular risk excluding those with diabetes mellitus or history of stroke were recruited from 102 clinics in the United States and Puerto Rico. Participants were randomized to a SBP goal of <120 mm Hg (intensive treatment) or <140 mm Hg (standard treatment) and received treatment for 3.3 years. In-person cognitive assessment follow-up occurred through July 2018. Continued ascertainment of cognitive status by telephone began in December 2019 for participants who had not withdrawn consent or been previously adjudicated with probable dementia, but provided consent for future research. Data were analyzed using survival analyses. Of 9,361 randomized participants, 7,221 (77%) were eligible to be re-contacted. Cognitive status of 4,232 (59%) was ascertained (mean age 67 years, 36% female). We accrued a total of 216 new cases of probable dementia, less than our target of 326. Over a median follow-up of 7 years, 248 participants of the intensive treatment group (8.5 per 1,000 person-years) were adjudicated with probable dementia, compared with 293 participants (10.2 per 1,000 person-years) in the standard treatment group (hazard ratio [HR], 0.86; 95% CI, 0.72-1.02). Consistent with earlier results from the trial, the rate of both mild cognitive impairment (MCI; HR, 0.87 95% CI, 0.76-1.00) and a composite of MCI or probable dementia was lower with intensive treatment (HR, 0.89; 95% CI, 0.79, 0.99). Among ambulatory adults with hypertension and high cardiovascular risk, intensive treatment vs standard treatment of SBP for 3.3 years resulted in a lower risk of MCI and cognitive impairment including MCI or probable dementia, but not for probable dementia alone. This study provides Class II evidence that intensively reducing SBP (target <120 mm Hg) decreases the risk of cognitive impairment in individuals aged 50 years and older with hypertension. Clinical trial number NCT01206062.


  • Open Access

    The Types and Consistency of Participant‐Specified Proxies During SPRINT

    by Sarah A. Gaussoin, Byron C Jaeger, Alan J. Lerner, Letitia H. Perdue, Stephen R. Rapp, David M. Reboussin, Jeff D. Williamson

    Background: For clinical trials or patient care, reports from a person familiar with the trajectory of a participant’s cognitive and functional performance (i.e., proxies) may improve adjudication of events, such as mild cognitive impairment and dementia. Proxies offer a unique perspective on cognitive status that is different from what is captured through standard cognitive examinations. Clinical trials in which cognitive status is adjudicated, such as the Systolic Blood Pressure Intervention (SPRINT) trial, provide information about the contributions and consistency of proxies throughout extended follow‐up.Method: SPRINT participants named proxies and relationship to them at study onset. Proxies provided information for the Functional Activities Questionnaire and Dementia Questionnaire. We collapsed proxy relationships into seven categories and evaluated the proportion of proxies in each category at baseline and how frequently the same proxy was retained to the last visit. We explored associations between proxy relationship and various baseline demographics and examined the association between not having a proxy, as well as proxy relationship, and adjudicated outcome.Result: Of the 9,361 randomized SPRINT participants (35.6% female, mean age 67.9 years), 7,586 (81%) participants listed a proxy relationship from which we identified 7 categories: spouse/partner (51.7%), child (23.6%), sibling (8.7%), other family member (6.2%), and unrelated (8.8%). Male participants were more likely to name a spouse as their proxy (64%) while female participants more likely to name a child (42%). The overall consistency of proxy continuation between the baseline and final SPRINT visit (mean 6.9 years) was 90.7%. Proxy consistency from first visit to last visit for a child was 94.8%, spouse/partner (91.9%) brother/sister (87.5%), other family member (82.4%), non‐related (81.2%), and parent (78.2%). Adjudications that resulted in ‘Cannot Classify’ were greatest for proxies who were parents (15%) followed by none (12%), sibling and grandchild (9%), child and unrelated (7%), spouse and other family (6%).Conclusion: The majority of proxies in SPRINT were immediate family members (spouse, child, or sibling). Over 90% of identified proxies at baseline continued to be available over a mean of almost 7 years of follow‐up. Not having a proxy available led to a higher rate of ‘cannot classify’ adjudications.

  • Open Access

    Feasibility of Remote Administration of the Uniform Data Set-Version 3 for Assessment of Older Adults With Mild Cognitive Impairment and Alzheimer’s Disease

    by Bonnie C Sachs, Lauren A Latham, James R Bateman, Mary Jo Cleveland, Mark A Espeland, Eric Fischer, Sarah A Gaussoin, Iris Leng, Stephen R Rapp, Samantha Rogers, et al.

    Assess the feasibility and concurrent validity of a modified Uniform Data Set version 3 (UDSv3) for remote administration for individuals with normal cognition (NC), mild cognitive impairment (MCI), and early dementia. Participants (N = 93) (age: 72.8 [8.9] years; education: 15.6 [2.5] years; 72% female; 84% White) were enrolled from the Wake Forest ADRC. Portions of the UDSv3 cognitive battery, plus the Rey Auditory Verbal Learning Test, were completed by telephone or video within ~6 months of participant’s in-person visit. Adaptations for phone administration (e.g., Oral Trails for Trail Making Test [TMT] and Blind Montreal Cognitive Assessment [MoCA] for MoCA) were made. Participants reported on the pleasantness, difficulty, and preference for each modality. Staff provided validity ratings for assessments. Participants’ remote data were adjudicated by cognitive experts blinded to the in person-diagnosis (NC [N = 44], MCI [N = 35], Dementia [N = 11], or other [N = 3]). Remote assessments were rated as pleasant as in-person assessments by 74% of participants and equally difficult by 75%. Staff validity rating (video = 92%; phone = 87.5%) was good. Concordance between remote/in-person scores was generally moderate to good (r = .3 −.8; p < .05) except for TMT-A/OTMT-A (r = .3; p > .05). Agreement between remote/in-person adjudicated cognitive status was good (k = .61–.64). We found preliminary evidence that older adults, including those with cognitive impairment, can be assessed remotely using a modified UDSv3 research battery. Adjudication of cognitive status that relies on remotely collected data is comparable to classifications using in-person assessments.


  • Open Access

    Impact of Multivitamin‐Mineral and Cocoa Extract on Incidence of Mild Cognitive Impairment and Dementia: Results from the Cocoa Supplement and Multivitamin Outcomes Study for the Mind COSMOS‐Mind

    by Stephen R. Rapp, Bonnie C. Sachs, Benjamin J. Williams, Sarah A. Gaussoin, Laura D Baker, JoAnn E. Manson, Howard D. Sesso, Sally A. Shumaker, Mark A. Espeland, COSMOS‐Mind Research Group

    Background: COSMOS‐Mind, a large, randomized placebo‐controlled pragmatic trial in older adults, recently reported that daily supplementation with multivitamin‐mineral, but not cocoa extract, benefited global cognition. We assessed effects of these supplements on prespecified secondary outcomes of mild cognitive impairment (MCI) and all‐cause dementia (DM). We also assessed treatment‐related cognitive trajectories leading to conversion to MCI or dementia.Method: COSMOS‐Mind (N = 2262) administered a telephone‐based cognitive battery at baseline and annually for 3 years. Proxies of participants meeting criteria for suspected cognitive impairment based on a cognitive screener (TICSm) were interviewed. An expert panel adjudicated cognitive status. Incidence rates of MCI, and separately DM, were compared among arms with proportional hazards regression. Changes in cognitive trajectories leading to MCI and DM were assessed with linear models.Result: At baseline, adjudication for suspected cognitive impairment was triggered for 419 (20%) participants, yielding adjudications of 217 (10%) MCI and 4 (0.2%) DM cases. During follow‐up, triggers were less frequent in the MVM than placebo arms: hazard ratio = 0.73 (p = 0.04). Across 3 years, 110 incident MCI and 14 incident DM cases were adjudicated. Incidence rates of these outcomes did not vary by assignment to multivitamin‐mineral or cocoa extract (all p≥0.05), however statistical power was low. Incident MCI was associated with a marked decline in cognitive function from the previous year (p<0.001). When participants assigned to multivitamin‐mineral versus placebo converted to MCI, their scores for global cognition (p = 0.03) and executive function (p<0.001) were higher and had declined less relative to the previous year (p = 0.03 for global cognition; p = 0.004 for executive function). Daily cocoa extract use did not attenuate cognitive decline leading up to MCI.Conclusion: COSMOS‐Mind does not provide evidence that cocoa extract or multivitamin‐mineral therapy lowers risk of incident MCI or DM. Multivitamin‐mineral therapy, but not cocoa extract, may provide cognitive resilience countering conversion to MCI.

  • Open Access

    Examining a telecognitive assessment‐derived Preclinical Alzheimer’s Cognitive Composite, the tPACC, for cognitive migration over one year in community‐dwelling older adults

    by Tugce Duran, James R. Bateman, Sarah A. Gaussoin, Melissa M. Rundle, Stephanie E. Okonmah‐Obazee, Mark A. Espeland, Benjamin J. Williams, Tim M. Hughes, Suzanne Craft, Samuel N. Lockhart, et al.

    Background: ADRD clinical trials often target preclinical disease, where hope of averting the pathologic cascade and eventual cognitive decline remains highest. The preclinical Alzheimer’s cognitive composite (PACC5) was developed for in‐person administration to capture subtle cognitive decline. Early cognitive fluctuations may inform multidirectional disease progression, defined as cognitive migration. It is desirable to have a harmonized composite measurement derived from in‐person and remote assessments for detecting cognitive migration.Method: We examined in‐person data from 417 adults (70.6±8.0y) from the Wake Forest ADRC Clinical Core, who received MRI, clinical evaluation and cognitive testing. The primary outcome was cognitive migration status determined by global CDR (0 and 0.5) increase/decrease between baseline (BL) and follow‐up (mean difference = 13.9 months): CDR‐0 Stable (51% maintained CDR‐0), CDR‐0.5 Stable (27% maintained CDR‐0.5), Reverter+ (13% migrated from CDR‐0.5 to CDR‐0) and Migrant− (9% migrated from CDR‐0 to CDR‐0.5). In‐person PACC5 was calculated (RAVLT Delayed Recall, Digit Symbol Coding [DSC], semantic fluency, Craft Story Delayed Verbatim, total MMSE) using BL participants with global CDR = 0 as reference. tPACC used measurements available at both in‐person and remote visits with minor modifications from PACC5: Montreal Cognitive Assessment (MoCA) replaced MMSE and DSC not included. We performed intraclass correlation coefficient (ICC) analysis and generated Bland‐Altman plots for BL tPACC and PACC5. We also evaluated associations between tPACC and neuroimaging.Result: Participant characteristics and group differences in MRI markers are in Table 1. Bland‐Altman plots show differences and mean of tPACC and PACC5 (dashed line: ±1.96 SD, solid line: mean difference/bias). 92% of values lie within limit of agreement, indicating good agreement (overall ICC = .960, 95%CI = [.952, .967]), between tPACC and PACC5 in each group (Figure 1). At BL, there was a significant absolute agreement between in‐person tPACC and PACC5 in all groups (Figure 1). tPACC showed significant associations (Table 2) with Temporal Meta ROI thickness, hippocampal volume as % head size (ICV) and white matter hyperintensities (logWMH controlled for ICV) overall and in some cognitive migration groups.Conclusion: There is generally good agreement between BL tPACC and PACC5 across cognitive migration groups. BL tPACC may predict BL neuroimaging based on cognitive migration status. Longitudinal tPACC examination is warranted.

  • Open Access

    Examining a telecognitive assessment‐derived Preclinical Alzheimer’s Cognitive Composite, the tPACC, for cognitive migration over one year in community‐dwelling older adults

    by Tugce Duran, James R. Bateman, Sarah A. Gaussoin, Melissa M. Rundle, Stephanie E. Okonmah‐Obazee, Mark A. Espeland, Benjamin J. Williams, Tim M. Hughes, Suzanne Craft, Samuel N. Lockhart, et al.

    Background: ADRD clinical trials often target preclinical disease, where hope of averting the pathologic cascade and eventual cognitive decline remains highest. The preclinical Alzheimer’s cognitive composite (PACC5) was developed for in‐person administration to capture subtle cognitive decline. Early cognitive fluctuations may inform multidirectional disease progression, defined as cognitive migration. It is desirable to have a harmonized composite measurement derived from in‐person and remote assessments for detecting cognitive migration.Method: We examined in‐person data from 417 adults (70.6±8.0y) from the Wake Forest ADRC Clinical Core, who received MRI, clinical evaluation and cognitive testing. The primary outcome was cognitive migration status determined by global CDR (0 and 0.5) increase/decrease between baseline (BL) and follow‐up (mean difference = 13.9 months): CDR‐0 Stable (51% maintained CDR‐0), CDR‐0.5 Stable (27% maintained CDR‐0.5), Reverter+ (13% migrated from CDR‐0.5 to CDR‐0) and Migrant‐ (9% migrated from CDR‐0 to CDR‐0.5). In‐person PACC5 was calculated (RAVLT Delayed Recall, Digit Symbol Coding [DSC], semantic fluency, Craft Story Delayed Verbatim, total MMSE) using BL participants with global CDR = 0 as reference. tPACC used measurements available at both in‐person and remote visits with minor modifications from PACC5: Montreal Cognitive Assessment (MoCA) replaced MMSE and DSC not included. We performed intraclass correlation coefficient (ICC) analysis and generated Bland‐Altman plots for BL tPACC and PACC5. We also evaluated associations between tPACC and neuroimaging.Result: Participant characteristics and group differences in MRI markers are in Table 1. Bland‐Altman plots show differences and mean of tPACC and PACC5 (dashed line: ±1.96 SD, solid line: mean difference/bias). 92% of values lie within limit of agreement, indicating good agreement (overall ICC = .960, 95%CI = [.952, .967]), between tPACC and PACC5 in each group (Figure 1). At BL, there was a significant absolute agreement between in‐person tPACC and PACC5 in all groups (Figure 1). tPACC showed significant associations (Table 2) with Temporal Meta ROI thickness, hippocampal volume as % head size (ICV) and white matter hyperintensities (logWMH controlled for ICV) overall and in some cognitive migration groups.Conclusion: There is generally good agreement between BL tPACC and PACC5 across cognitive migration groups. BL tPACC may predict BL neuroimaging based on cognitive migration status. Longitudinal tPACC examination is warranted.

  • Open Access

    Evaluating Dementia Neuroanatomic Risk of a Clinical Cohort Using MRI

    by Ramon Casanova, Ryan Barnard, Fang‐Chi Hsu, Samuel N. Lockhart, James R. Bateman, Melissa M. Rundle, Sarah A. Gaussoin, Tim M. Hughes, Christopher T. Whitlow, Kiran K Solingapuram Sai, et al.

    Background: MRI is a widely used modality to evaluate dementia risk. Here, we extend previous work by estimating the Alzheimer’s disease pattern similarity (AD‐PS) scores for participants of a community‐dwelling older adult cohort to evaluate neuroanatomic risk of AD using MRI.Method: Baseline MRI data were available from 522 participants from the Wake Forest Alzheimer’s Disease Research Center’s (ADRC) Clinical Core with mean age 70.2, 81.2% White and 17.6% African American. Of those, 253 were cognitively impaired (dementia and mild cognitive impairment (MCI)) and 138 underwent [11C]PiB PET (MCI = 48 and dementia = 19). Global PiB SUVR was averaged from a cortical region of interest sensitive to early AD. Participants were classified as amyloid positivity using a previously defined threshold (≥1.21 SUVR). AD‐PS scores were estimated based on GM probability maps according to previously reported machine learning methodology[1]. High‐dimensional classifiers were trained using ADNI MRI data. To generate the AD‐PS scores, MRI data from the ADRC cohort was provided as input to the classifiers.We investigated associations that AD‐PS scores [range 0‐1] had with amyloid positivity and cognitive impairment. All analyses were adjusted for age, sex, race and education. AD‐PS scores discrimination of participants with dementia versus normal cognition (CN) was compared to hippocampal volume and cortical thickness in temporal regions based meta‐ROI which are sensitive to AD.Result: AD‐PS scores were strongly associated with cognitive impairment: OR = 4.1, CI: 95% [2.9‐5.9], pReferences [1] Casanova et. al., Alzheimer’s & Dementia, 2021, PMID:34310039.